Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial
10.1016/j.ejca.2016.09.013 · doi-reference
Awakening the immune system with radiation: optimal dose and fractionation
10.1016/j.canlet.2015.03.024 · doi-reference
Radiation as an immunological adjuvant: current evidence on dose and fractionation
10.3389/fonc.2012.00153 · doi-reference
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer
10.1158/0008-5472.can-12-2606 · doi-reference
Immune checkpoint inhibitors: new insights and current place in cancer therapy
10.1002/phar.1643 · doi-reference
Immunotherapy of ovarian cancer: the role of checkpoint inhibitors
10.1155/2015/191832 · doi-reference
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
10.1056/nejmoa1414428 · doi-reference
Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models
10.1007/s00262-016-1863-0 · doi-reference
Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma
10.1371/journal.pone.0129954 · doi-reference
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
10.1186/1479-5876-11-5 · doi-reference
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
10.1016/j.ejca.2012.07.015 · doi-reference
A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity
10.1158/1078-0432.ccr-10-2921 · doi-reference
Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors
10.1089/15368590152740707 · doi-reference
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF
10.1038/jid.2012.376 · doi-reference
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma
10.1158/1078-0432.ccr-11-1203 · doi-reference
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses
10.1158/2326-6066.cir-13-0206 · doi-reference
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
10.1007/s00262-015-1704-6 · doi-reference
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
10.1016/j.ejca.2010.07.033 · doi-reference
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
10.18632/oncotarget.6055 · doi-reference
The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer
10.1158/1078-0432.ccr-08-0157 · doi-reference
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
10.1182/blood-2008-05-160747 · doi-reference
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature
10.1016/j.leukres.2015.04.005 · doi-reference
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
10.1182/blood.v99.5.1659 · doi-reference
NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
10.1186/s12967-015-0397-0 · doi-reference
Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects
10.1158/1078-0432.ccr-14-2676 · doi-reference
In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments
10.1158/0008-5472.can-15-2644 · doi-reference
Interleukin 12: still a promising candidate for tumor immunotherapy?
10.1007/s00262-014-1523-1 · doi-reference
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
10.1172/jci58814 · doi-reference
Interleukin-12 and the regulation of innate resistance and adaptive immunity
10.1038/nri1001 · doi-reference
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production
10.4049/jimmunol.153.4.1697 · doi-reference
The IL-2 cytokine family in cancer immunotherapy
10.1016/j.cytogfr.2014.07.018 · doi-reference
Th1 cytokine-based immunotherapy for cancer
10.1016/s1499-3872(14)60305-2 · doi-reference
Using DNA, radiation therapy gets personal
10.1126/science.353.6306.1348 · doi-reference
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
10.1126/science.aad1329 · doi-reference
Combination of radiotherapy and vaccination overcome checkpoint blockade resistance
10.18632/oncotarget.9915 · doi-reference
The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
10.1080/2162402x.2015.1016709 · doi-reference
Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer
10.1158/1535-7163.mct-14-1015 · doi-reference
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
10.1158/2326-6066.cir-14-0069 · doi-reference
GM-CSF gene-transduced tumor vaccines
10.1016/j.ymthe.2005.02.012 · doi-reference
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
10.1126/scitranslmed.aaa4306 · doi-reference
